51. Restriction of HIV replication in infected T cells and monocytes by interferon-alpha.
- Author
-
Gendelman HE, Baca L, Turpin JA, Kalter DC, Hansen BD, Orenstein JM, Friedman RM, and Meltzer MS
- Subjects
- DNA, Viral analysis, Dose-Response Relationship, Drug, Gene Products, gag immunology, HIV genetics, HIV immunology, HIV Antigens analysis, HIV Core Protein p24, HIV Infections drug therapy, Humans, Interferon Type I administration & dosage, Monocytes drug effects, RNA, Viral analysis, Recombinant Proteins, T-Lymphocytes drug effects, Viral Core Proteins immunology, Virus Replication drug effects, HIV drug effects, Interferon Type I pharmacology, Monocytes microbiology, T-Lymphocytes microbiology
- Abstract
Human recombinant interferon-alpha (IFN alpha) restricted viral replication in human immunodeficiency virus- (HIV) infected T cells and monocytes. With T cells, reverse transcriptase (RT) activity in culture fluids was reduced threefold from that of control infected cells by IFN treatment, but HIV p24 antigen levels were unchanged. In contrast, levels of p24 antigen and RT activity in lysates of IFN-treated infected cells were threefold greater than those of controls. These differences suggest that the mechanism for IFN-induced antiviral effects in HIV-infected T cells resides in the terminal events (assembly and release) of the virus replication cycle. Monocytes treated with IFN at the time of virus challenge showed no p24 antigen or RT activity, no HIV-specific mRNA, and no proviral DNA in cells for up to 3 weeks after infection. IFN treatment of chronically infected monocytes also decreased virus replication, as assessed by p24 antigen, mRNA and RT detection assays. However, levels of proviral DNA in the IFN-treated and control HIV-infected cells were indistinguishable. The presence of large quantities of proviral DNA in cells with little or no evidence for active transcription documents a situation approaching true microbiological latency.
- Published
- 1990
- Full Text
- View/download PDF